Managing Your Treatment Plan
At a Glance
UCTD treatment is individualized: medicines are chosen for symptoms and whether the disease affects an organ. Hydroxychloroquine requires dosing based on your weight and kidney function plus regular eye screening, while NSAIDs and immunosuppressants need careful safety planning.
Because Undifferentiated Connective Tissue Disease (UCTD) covers a wide range of symptoms, there is no single “one-size-fits-all” treatment plan [1]. Instead, your care is symptom-directed, meaning your doctor will tailor medications to the specific ways the disease affects your body [2].
The primary goal of treatment is to control current symptoms—like joint pain or skin rashes—and to manage the immune system [3][4].
Standard Medical Management
For many patients, UCTD is managed with a mild autoimmune regimen [1][2]:
- Hydroxychloroquine (HCQ): This is frequently used for specific inflammatory, skin, or joint manifestations. It helps modulate the immune system, though its ability to definitively prevent progression is not fully established [1].
- NSAIDs: Non-Steroidal Anti-Inflammatory Drugs (like ibuprofen or naproxen) are sometimes used for joint and muscle pain. Safety Warning: Daily or long-term NSAID use carries significant risks, including gastrointestinal bleeding, kidney injury, fluid retention, and elevated blood pressure. They can also interact with other medications and may be unsafe in pregnancy. Do not combine NSAIDs or assume over-the-counter options are safe for long-term use without clinical supervision [1].
- Glucocorticoids (Steroids): Medications like prednisone may be used at very low doses for short periods to “quiet” a flare-up of inflammation [1][3].
- Immunosuppressants: Medications like azathioprine, methotrexate, or mycophenolate are selected when there is documented organ involvement or persistent, clinically significant disease [1][5][6]. Safety Warning: These drugs increase infection risk and require careful vaccination planning. Furthermore, drugs like methotrexate and mycophenolate are strictly unsafe in pregnancy and require reliable contraception. Always follow exact clinician instructions for blood and liver monitoring.
Focus on Hydroxychloroquine Safety
While hydroxychloroquine is generally well-tolerated, it requires careful dosing and lifelong monitoring to avoid rare but serious side effects [7][4].
Correct Dosing
The prescriber must determine your dose based on indication, weight, kidney function, and interacting medicines. Current ophthalmology guidelines recommend that your daily dose should generally not exceed 5 mg per kilogram of your actual body weight [7][8]. People with kidney disease may need much less [9][10].
Protecting Your Vision
The most significant long-term risk of HCQ is retinal toxicity, where the medication builds up in the back of the eye and damages vision [9]. To stay safe, you must follow a strict screening schedule:
- Baseline Exam: You should have a thorough eye exam within the first year of starting the drug to check for any pre-existing eye conditions [8][9].
- Annual Screening: Generally begins after five years of treatment [8]. If you have high-risk factors like chronic kidney disease, older age, or take medications like tamoxifen, your doctor may start these annual exams sooner [10][9].
- Specific Tests: A standard vision test is not enough. You must have Spectral-Domain OCT (a high-resolution “map” of your retina) and automated visual field testing [8][9]. Patients of Asian ancestry may need wider visual field tests, as toxicity can appear differently [11].
Other Potential Risks
While rare, HCQ can affect other parts of the body:
- Heart: It can sometimes cause QT prolongation (a change in the heart’s electrical rhythm) or cardiomyopathy (weakening of the heart muscle) [12][13]. ECG assessment is individualized, especially if you have cardiac disease or take other QT-prolonging drugs [12].
- Muscles: In rare cases, it can cause muscle weakness (myopathy) [14].
- Blood Sugar: Rarely, it can cause low blood sugar (hypoglycemia) [15].
Non-Drug Measures
Practical lifestyle measures complement medical treatment. Use sun protection if you are photosensitive. For Raynaud’s, keep your whole body warm (not just the hands) and avoid nicotine. Pacing your activity and joint-protection techniques can also help manage fatigue and pain.
Common questions in this guide
How is undifferentiated connective tissue disease treated?
What should I know about hydroxychloroquine dosing for UCTD?
What eye tests do I need while taking hydroxychloroquine?
Are NSAIDs safe for daily joint pain in UCTD?
Can I take UCTD immunosuppressants during pregnancy?
What can I do besides medicine to manage UCTD symptoms?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is my current dose of hydroxychloroquine, and does my kidney function mean I need a lower dose?
- 2.Does my medical history or other medications require me to have a baseline ECG before starting hydroxychloroquine?
- 3.When should I schedule my baseline eye exam, and can you confirm it will include spectral-domain OCT and automated visual field testing?
- 4.If we start an immunosuppressant, what specific organ involvement are we targeting, and what are the pregnancy and infection precautions?
- 5.What are the safest options for managing my daily joint pain, considering the risks of long-term NSAID use?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (15)
- 1
Undifferentiated Connective Tissue Disease: Comprehensive Review.
Rubio J, Kyttaris VC
Current rheumatology reports 2023; (25(5)):98-106 doi:10.1007/s11926-023-01099-5.
PMID: 36884206 - 2
Undifferentiated connective tissue disease: state of the art on clinical practice guidelines.
Antunes M, Scirè CA, Talarico R, et al.
RMD open 2018; (4(Suppl 1)):e000786 doi:10.1136/rmdopen-2018-000786.
PMID: 30886731 - 3
A Case of Undifferentiated Connective Tissue Disease with Bilateral Auricular Polychondritis Manifestations: A Rare Clinical Association.
Nigro A, Santarcangelo P, Bonelli A, et al.
The American journal of case reports 2025; (26()):e946827 doi:10.12659/AJCR.946827.
PMID: 40336182 - 4
Longitudinal analysis of quality of life in patients with undifferentiated connective tissue diseases.
Iudici M, Irace R, Riccardi A, et al.
Patient related outcome measures 2017; (8()):7-13 doi:10.2147/PROM.S117767.
PMID: 28203114 - 5
Diplopia as the herald of fulminant myocarditis in undifferentiated connective tissue disease: a case report.
Chen Y, Li Y, Zhang R, et al.
Frontiers in cardiovascular medicine 2026; (13()):1848981 doi:10.3389/fcvm.2026.1848981.
PMID: 42325674 - 6
Exostosin 1/exostosin 2-associated membranous nephropathy in undifferentiated connective tissue disease: a case report and literature review.
Ye H, Jiang X, Wu B, et al.
BMC nephrology 2025; (26(1)):665 doi:10.1186/s12882-025-04596-0.
PMID: 41291566 - 7
American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity.
Rosenbaum JT, Costenbader KH, Desmarais J, et al.
Arthritis & rheumatology (Hoboken, N.J.) 2021; (73(6)):908-911 doi:10.1002/art.41683.
PMID: 33559327 - 8
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Marmor MF, Kellner U, Lai TY, et al.
Ophthalmology 2016; (123(6)):1386-94.
PMID: 26992838 - 9
Special AAO Report: Recommendations on Screening for Hydroxychloroquine Retinopathy (2025 Revision).
Marmor MF, Ahn SJ, Ehlers JP, et al.
Ophthalmology 2026; (133(4)):439-450 doi:10.1016/j.ophtha.2025.11.001.
PMID: 41232611 - 10
Risk Factors for Hydroxychloroquine Retinopathy and Its Subtypes.
Jorge AM, Melles RB, Marmor MF, et al.
JAMA network open 2024; (7(5)):e2410677 doi:10.1001/jamanetworkopen.2024.10677.
PMID: 38722628 - 11
Hydroxychloroquine retinopathy.
Yusuf IH, Sharma S, Luqmani R, Downes SM
Eye (London, England) 2017; (31(6)):828-845 doi:10.1038/eye.2016.298.
PMID: 28282061 - 12
American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity.
Desmarais J, Rosenbaum JT, Costenbader KH, et al.
Arthritis & rheumatology (Hoboken, N.J.) 2021; (73(12)):2151-2160 doi:10.1002/art.41934.
PMID: 34697918 - 13
Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic.
Gagnon LR, Sadasivan C, Yogasundaram H, Oudit GY
Current heart failure reports 2022; (19(6)):458-466 doi:10.1007/s11897-022-00581-y.
PMID: 36167917 - 14
Hydroxychloroquine-induced autophagic vacuolar myopathy with mitochondrial abnormalities.
Khosa S, Khanlou N, Khosa GS, Mishra SK
Neuropathology : official journal of the Japanese Society of Neuropathology 2018; (38(6)):646-652 doi:10.1111/neup.12520.
PMID: 30411412 - 15
Hydroxychloroquine-Induced Hypoglycemia in a Non-Diabetic Patient with Chronic Kidney Disease and Rheumatoid Arthritis.
English K
Current health sciences journal 2025; (51(4)):560-563 doi:10.12865/CHSJ.51.04.15.
PMID: 42006110
This page explains UCTD medicines, monitoring, and lifestyle measures for education; it does not replace medical advice. Ask your rheumatologist or another healthcare professional before changing medication, especially during pregnancy or if you have kidney, eye, or heart conditions.
Get notified when new evidence is published on Undifferentiated connective tissue syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.